These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Screening Antibodies Raised Against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays

submitted on 01.09.2020, 15:38 and posted on 02.09.2020, 07:34 by Jason Cantera, David Cate, Allison Golden, Roger Peck, Lorraine Lillis, Gonzalo Domingo, Eileen Murphy, Bryan Barnhart, Caitlin E Anderson, Luis F Alonzo, Veronika Glukhova, Gleda Hermansky, Brianda Barrios-Lopez, Ethan Spencer, Samantha Kuhn, Zeba Islam, Benjamin Grant, Lucas Kraft, Karine Herve, Valentine de Puyraimond, Yuri Hwang, Puneet K Dewan, Bernhard H Weigl, Kevin P Nichols, David Boyle

The spike glycoprotein of SARS-CoV-2 is a highly conserved surface protein and as such may represent a good target for immunoassay detection. We screened a variety of antibodies that were reactive to the S glycoprotein in a highly sensitive liquid immunoassay format and also on paper-based or lateral flow assay (LFA) to assess their analytical performance. Our findings included significant variation in performance when using different sources of S antigen. We identified several antibody pairs that had an LOD of below 10 pg/mL in the liquid immunoassay format with the lowest being 3 pg/mL. The antibodies were highly specific to SARS-Cov-2 based on cross reactivity screening with other human CoVs. The LFA screening found some different optimal antibody pairs from the pool of candidate antibodies used but a several antibodies were observed to have high performance with either immunoassay format.


INV-016821 BMGF



Email Address of Submitting Author




United States

ORCID For Submitting Author


Declaration of Conflict of Interest

BB, LK, KH, VP and YH are employees of AbCellera Biologics. All other authors have no competing interests.

Version Notes

Version 1.